Global HPAPI and Cytotoxic Drug Manufacturing Market

SEATTLE, May 25, 2022 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the HPAPI and Cytotoxic Drugs Manufacturing Market is estimated to reach US$27.78 billion in 2022 and is expected to grow at a CAGR of 8.0% during the forecast period (2022-2030).

Key trends and analysis of Global HPAPI and Cytotoxic Drug Manufacturing Market:

Major market trends include increasing product approvals, increasing prevalence of chronic diseases, increasing research and development activities, and inorganic growth activities such as collaborations, etc.

The major players are engaged in new product launches which are expected to drive the growth of the global HPAPI and cytotoxic drug manufacturing market during the forecast period. For example, on March 7, 2022, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States, announced the launch of a first generic version of Revlimid (lenalidomide capsules) in the United States. It is a prescription medicine that is used to treat multiple myeloma in combination with other diseases.

The market players are engaging in the expansion of their manufacturing plant which is expected to drive the growth of the global HPAPI and cytotoxic drug manufacturing market over the forecast period. For example, in July 2020, Helsinn Advanced Synthesis SA (HAS), a manufacturing subsidiary of Helsinn Healthcare that develops and manufactures active pharmaceutical ingredients (APIs), cGMP advanced intermediates, high potency APIs (HPAPIs) and anti-cancer compounds, announced the opening of its largest bay dedicated to anti-cancer drugs at its production plant in Biasca, Switzerland. Clinical and commercial cancer APIs will be developed, analyzed and manufactured in the novel cancer array.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1312

HPAPI and Cytotoxic Drugs Manufacturing Market Report Coverage

Report attributes Details
Market size in 2022 $27.78 billion
Projection of the market size in 2030 $51.53 billion
CAGR (2022-2030) 8.0%
The biggest market North America
Growth engines
  • Increase inorganic activities such as market player collaborations
  • Increase product endorsements by market players
  • Increase in Manufacturing Facilities by Market Players
Segmentation By drug origin, by drug type, by type of pharmacological molecule and by application
Regional analysis North America (US, Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Europe (UK, Germany, Italy, France, Spain, Russia and Rest of Europe) , APAC (China, Japan, India, South Korea, Australia, ASEAN and rest of Asia-Pacific), ME (GCC countries, Israel and rest of Middle East) and Africa (South Africa, North Africa and Central Africa).
Key companies covered Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation

Market players are focusing on inorganic activities, such as signing deals, which is expected to drive the growth of the market over the forecast period. For example, in July 2021, Novasep, a pharmaceutical and biopharmaceutical technology provider, announced the signing of a manufacturing services agreement with Exelixis, a commercially successful, oncology-focused U.S. biotechnology company, for clinical cGMP production. of XB002, a new generation antibody-drug conjugate (ADC) targeting tissue factor for applications in oncology.

Main market takeaways:

The market players are engaging in inorganic activities, such as acquisitions, which is expected to drive the growth of the global HPAPI and cytotoxic drug manufacturing market during the forecast period. For example, in May 2020, Abbvie Contract Manufacturing (AbbVie Inc.) acquired Allergan Plc., for $63 billion. The acquisition is expected to expand the product portfolio and strengthen the company’s position in the HPAPI and cytotoxic drug manufacturing market.

Among the regions, North America is expected to hold a dominant position in the global HPAPI and cytotoxic drug manufacturing market over the forecast period, owing to the increase in product approvals in the region. For example, in December 2020, Amgen Inc., a US-based multinational biopharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved RIABNI (rituximab-arrx), a biosimilar of Rituxan (rituximab), for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and granulomatosis with polyangiitis (MPA).

Competitive Landscape:

Key players operating in the global HPAPI and cytotoxic drug manufacturing market include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation.

Buy now this research report @ https://www.coherentmarketinsights.com/insight/buy-now/1312

Market segmentation :

  • Global HPAPI and Cytotoxic Drugs Manufacturing Market, By Drug Origin:
    • HPAPI based on chemicals
    • Bio-Based HPAPI
  • Global HPAPI and Cytotoxic Drug Manufacturing Market, By Manufacturing Location:
    • In-house manufacturing
    • Outsourcing
  • Global HPAPI and Cytotoxic Drugs Manufacturing Market, By Drug Type:
    • New HPAPIs
    • Generic HPAPIs
  • Global HPAPI and Cytotoxic Drug Manufacturing Market, By Pharmacological Molecule Type:
  • Global HPAPI and Cytotoxic Drug Manufacturing Market, By Application:
    • Oncology
    • Respiratory
    • Ophthalmic disorders
    • Others
  • Global HPAPI and Cytotoxic Drug Manufacturing Market, By Region:
    • Latin America
      • By country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By country:
        • UK
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • The rest of Europe
    • Asia Pacific
      • By country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia-Pacific
    • Middle East
      • By country:
        • GCC
        • Israel
        • Rest of the Middle East
    • Africa
      • By country/region:
        • South Africa
        • central Africa
        • North Africa

Related Market Information Reports:
Oncology Radiopharmaceuticals Marketby type of test (radium-223 dichloride, sodium iodide I-131, lobenguane iodine-131, lutetium-177, yttrium-90, fludeoxyglucose F 18, gallium citrate Ga 67, technetium-99m and others), by route administration (oral and intravenous), by application (diagnosis and treatment), by end user (diagnostic centers, hospitals and clinics and research institutes) and by region (North America, Latin America, Europe, Asia-Pacific , Middle East & Africa) ) Size, Share, Prospects & Opportunities Analysis, 2021 – 2028

North America Respiratory Trainer Marketby product type (resistance trainers and endurance trainers), by technique (inspiratory muscle training (inspiratory flow resistive load and inspiratory pressure threshold load), expiratory muscle training and a combination of the two ), by Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease and Others), by End-User (Children and Adults), and by Country (US and Canada) – Size, Share, Prospect and Market Analysis opportunities, 2021 – 2028

About Us:

Consistent market information is a global market intelligence and advisory organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. Our head office is in India, with a sales office in the world’s financial capital in the USA and sales advisors in the UK and Japan. Our customer base includes players from various industries in more than 57 countries around the world. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insight in various post-COVID-19 industries and to continuing to deliver measurable and sustainable results to our clients.

Follow us: LinkedIn | Twitter


        

Comments are closed.